Chemomab Therapeutics Ltd DRC
Save
30.50M
Market cap
Current P/E
13.00x
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021.

Similar securities

Based on sector and market capitalization

Report issue